Answers are grounded in this paper and cite their sources.
Aim: To evaluate the clinical effectiveness of double cytotoxic drugs enhanced chemo immunotherapy in the treatment of advanced pancreatic cancer compared to single cytotoxic drugs by ultra-minimum incision personalized intra-tumoral chemo immunotherapy (UMIPIC-Therapy). Method: In study of UMIPIC with double drugs, 41 patients of pancreatic cancer were randomly divided into UMIPIC and ITCT groups, UMIPIC-D (n=30) treated with a proprietary therapeutic regimens including two cytotoxic drugs (Cytosine Arabinoside: Ara-C and Bleomycin: BLM) plus an oxidant and hapten, and ITCT-D (n=11) treated with same regimens intra-tumoral without the hapten. In UMIPIC with single drug, 45 patients of pancreatic cancer were randomly divided into two groups. UMIPIC-S (n=25) treated with a proprietary therapeutic regimens, it is composed of three intra-tumoral injections of a compound with an oxidant, a cytotoxic drug (Ara-C) and hapten. ITCT-S (n=20) uses an oxidant and a cytotoxic drug (Ara-C) without hapten. Both UMIPIC and ITCT use the same clinical therapeutic procedure. Results: For single drug, median survival was 6.45 months for UMIPIC-S vs 4.98 months for ITCT-S, (P<0.05), one year survival rate was 28% for UMIPIC-S vs 5% for ITCT-S (P<0.05). For double drugs, median survival was 15.5 months for UMIPIC-D vs 3 months in ITCT-D (P<0.01). The 6-month survival rate was 76.67% for UMIPIC-D vs 18.18% for ITCT-D (P<0.01) and 1-year survival rate for 56.67% UMIPIC-D vs 9.09% ITCT (P<0.01). Conclusion: UMIPIC for pancreatic cancer is a non-invasive and potentially effective therapy, and double cytotoxic drugs applied in the UMPIC-D revealed a significant advantage in prolonging the survival time.
No takes yet. Share an insight, caveat, or question.
Baofa Yu (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: